Opening Remarks from Rainer Blair
Danaher CEO Rainer Blair opens the company's fourth annual bioprocessing summit, framing it as a candid working forum on how biomanufacturing got here and the manufacturing challenges facing the next wave of modalities, anchored by patient stories like baby KJ.
Key Takeaways
- Manufacturing, not science, is now the rate-limiting step for biologic innovation and patient access.
- Historical bets — Dupixent, ADCs, Spinraza/oligonucleotides, GLP-1s — show breakthroughs come from investing in manufacturing capability ahead of demand.
- Baby KJ's personalized CRISPR therapy, made by Aldevron, IDT, and Cytiva in six months, shows what's possible but remains an unscalable N-of-1.
- Cytiva's technologies reached over 30 million patients (~95% of those treated with these modalities in 2025), a vantage point on where systems break.
- Closing the gap requires connected ecosystems and partnership across companies, disciplines, and regulators.
Sign in to read the full article.
Sign In